In this study, we aimed to investigate whether TB001, a novel dual GCGR/GLP-1R agonist, ameliorates renal fibrosis by inhibiting the PERK-mediated endoplasmic reticulum stress pathway, using well-established in vivo and in vitro models. This evidence concerns the gene EIF2AK3 and renal fibrosis.